Dual versus single antiplatelet therapy for secondary prevention in ischaemic stroke or transient ischaemic attack: A retrospective cohort study using real-world data

Norazida Ab Rahman¹, Wan Chung Law², Wan Asyraf Wan Zaidi³, Zariah Abdul Aziz⁴, Norsima Nazifah Sidek⁴, Irene Looi ⁵, Ming Tsuey Lim¹, Sarah Hui Li Pang¹, Wen Yea Hwong¹, and Sheamini Sivasampu¹

April 27, 2021

Abstract

Objective: This study aimed to assess effectiveness and safety outcomes of antiplatelet therapy for secondary prevention among patients with ischaemic stroke or transient ischaemic attack (TIA) in Malaysia. Method: Patients with a first ischaemic stroke/TIA between 2014 and 2017 were identified from stroke registry and data was linked with other data sources for information on antiplatelet exposure and outcome events. Exposure was defined as antiplatelet therapy at discharge from the index stroke hospitalisation and categorised into single antiplatelet therapy (SAPT) and dual antiplatelet therapy (DAPT) groups. Primary outcome was composite events of stroke, myocardial infarction, and all-cause death at up to one year after the index stroke in an intention-to-treat analysis. Results: Of 4434 patients included in the analysis, 6.7% were treated with DAPT and 93.3% were in SAPT group. During the 1-year follow-up, composite events occurred in 5.7% of patients in DAPT group and in 12.3% of SAPT (p<0.001). The rates of individual events were lower in DAPT group compared to SAPT: recurrent stroke (3.4% versus 4.8%), myocardial infarction (0.7% versus 1.9%), and all-cause death (1.7% versus 6.0%). Bleeding occurred in 1.3% of the DAPT group versus 1.6% of the SAPT. Multivariable-adjusted Cox regression analysis showed that rates of composite outcome was lower in the DAPT group compared to SAPT (HR 0.53, 95%CI 0.32, 0.86). Conclusion: In patients with ischaemic stroke/TIA, treatment with DAPT following the index stroke was associated with reduced risk of the composite events of stroke, myocardial infarction, and death. There appears to be similar risk of bleeding with DAPT versus SAPT.

TITLE

Dual versus single antiplatelet therapy for secondary prevention in ischaemic stroke or transient ischaemic attack: A retrospective cohort study using real-world data

RUNNING TITLE

Dual versus single antiplatelet therapy for secondary prevention in ischaemic stroke or transient ischaemic attack: A retrospective cohort study using real-world data

AUTHORS' NAMES AND AFFILIATIONS

¹Norazida Ab Rahman; BPharm (Hons), MSc (Epidemiology) (norazida@crc.gov.my)

¹Institute for Clinical Research

²Sarawak General Hospital

³Universiti Kebangsaan Malaysia Medical Centre

⁴Hospital Sultanah Nur Zahirah

⁵Hospital Seberang Jaya

- ²Wan Chung Law; MBBS, MRCP (lawwanchung1@gmail.com)
- ³Wan Asyraf Wan Zaidi; MD, MMed (Internal Medicine) (drwawz87@gmail.com)
- ^{4,5}Zariah Abdul Aziz; MBBS, MMed (Internal Medicine) (zaraziz_ayie@yahoo.com)

- 1. Institute for Clinical Research, National Institutes of Health, Ministry of Health, Selangor, Malaysia
- 2. Neurology Unit, Department of Medicine, Sarawak General Hospital, Ministry of Health, Sarawak, Malaysia
- 3. Neurology Unit, Department of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia
- 4. Department of Medicine, Hospital Sultanah Nur Zahirah, Ministry of Health, Terengganu, Malaysia
- 5. Clinical Research Centre, Hospital Sultanah Nur Zahirah, Ministry of Health, Terengganu, Malaysia
- 6. Department of Medicine, Hospital Seberang Jaya, Ministry of Health, Penang, Malaysia
- 7. Clinical Research Centre, Hospital Seberang Jaya, Ministry of Health, Penang, Malaysia
- 8. Clinical Research Centre, National Cancer Institute, Ministry of Health, Putrajaya, Malaysia
- 9. Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, the Netherlands

Corresponding author

Norazida Ab Rahman

Block B4, Institute for Clinical Research

National Institutes of Health (NIH), Ministry of Health Malaysia

No 1, Jalan Setia Murni U13/52

40170 Shah Alam, Selangor

Malaysia

Tel: +603 3362 8824

Email: norazida@crc.gov.my

Keywords: ischaemic stroke; TIA; antiplatelet; secondary prevention; registry

Hosted file

Draft4_manuscript.pdf available at https://authorea.com/users/410307/articles/519739-dual-versus-single-antiplatelet-therapy-for-secondary-prevention-in-ischaemic-stroke-or-transient-ischaemic-attack-a-retrospective-cohort-study-using-real-world-data

Hosted file

Draft4_table1.pdf available at https://authorea.com/users/410307/articles/519739-dual-versus-single-antiplatelet-therapy-for-secondary-prevention-in-ischaemic-stroke-or-transient-ischaemic-attack-a-retrospective-cohort-study-using-real-world-data

⁵Norsima Nazifah Sidek ; BPharm (Hons) (norsima@crc.moh.gov.my)

^{6,7}Irene Looi ; MBBS, FRCP (irenelooi@yahoo.com)

¹Ming Tsuey Lim; BPharm (Hons), MSc (mtlim2000@yahoo.com)

 $^{^{1,8} {\}rm Sarah}$ Hui LiPang ; MD $(sarahpang_my@yahoo.com)$

^{1,9}Wen Yea Hwong; MBBS, MSc (Epidemiology), PhD (amyhwong@crc.gov.my)


¹Sheamini Sivasampu; MBBS, MMed (Public Health) (sheamini@crc.gov.my)


Hosted file

Draft4_table2.pdf available at https://authorea.com/users/410307/articles/519739-dual-versus-single-antiplatelet-therapy-for-secondary-prevention-in-ischaemic-stroke-or-transient-ischaemic-attack-a-retrospective-cohort-study-using-real-world-data

Hosted file

Draft4_table3.pdf available at https://authorea.com/users/410307/articles/519739-dual-versus-single-antiplatelet-therapy-for-secondary-prevention-in-ischaemic-stroke-or-transient-ischaemic-attack-a-retrospective-cohort-study-using-real-world-data







Number at risk SAPT 4136 3958 3661 DAPT 298 288 276 0 30 60 3388 2996 1686 1587 1138 1034 180 2 Days

180 210

Days